TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.
Storytelling to Support TB Preventive Treatment (TPT)
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…
Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health
Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
The Right to Prevent TB
It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.
New HIV Prevention Research Fact Sheet
HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…
Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet
HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…
What’s on the Horizon for Long-Acting Pre-Exposure Prophylaxis (PrEP)? Fact Sheet
Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future…
Treatment Action Group Statement on Early Findings from HPTN 084
Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.